CIR of MFC-MRD and MFC-LSC-MRD by treatment arm. ELN intermediate-I risk patients are broken down by treatment arm (ie, standard [Stand.] vs clofarabine [Clofa] 10 mg in gray or blue, respectively) and presence or absence of MFC-MRD (A) or MFC-LSC-MRD (B) using previously published cutoffs (ie, ≥0.1% after chemotherapy cycle 2 is called MFC-MRD^positive, and ≥0.0000% after chemotherapy cycle 2 is called MFC-LSC-MRD^positive15 ). (A) MFC-MRD^negative patients treated with clofarabine have a lower incidence of relapse than MFC-MRD^negative patients in the standard arm. In parallel, MFC-MRD^positive patients with clofarabine have a lower incidence of relapse than MFC-MRD^positive patients without clofarabine. (B) Comparable to MFC-MRD, MFC-LSC-MRD shows similar results; MFC-LSC-MRD^negative patients treated with clofarabine have a distinct lower incidence of relapse than MFC-LSC-MRD^negative patients in the standard arm. In parallel, MFC-LSC-MRD^positive patients with clofarabine have a lower incidence of relapse than MFC-LSC-MRD^positive patients without clofarabine. P log-rank statistics are shown when significant.